Financial outcomes of high-flow nasal cannula use for bronchiolitis on the general pediatric floor.
High-flow nasal cannula (HFNC) is an increasingly common treatment utilized for bronchiolitis on general pediatric hospital floors. This could present a financial burden for hospitals if reimbursement has not accounted for the increased costs associated with increased HFNC use. Pediatric Health Information System and Revenue Management Program data set discharges from 2018 to 2019 were utilized to calculate the ratio of reimbursements to costs as a cost coverage ratio (CCR). The CCR was compared by HFNC use, the severity of illness, and payor type. The CCR was highest at 1.68 for children with high severity and HFNC use but varied greatly by payor. The lowest CCR at 0.77 was seen for children with low severity and public insurance and indicated potential financial losses for these patients. This was lower than low-severity patients on HFNC with private payors (1.68) and high-severity patients on HFNC with public payors (1.18).
J Hosp Med
Humans; Child; Infant; Cannula; Intensive Care Units, Pediatric; Bronchiolitis; Length of Stay; Hospitals, General
Cannula; Pediatric Intensive Care Units; Bronchiolitis; Length of Stay; General Hospitals
Hartley J, Bettenhausen J, Hall M, Synhorst D, Gay J. Financial outcomes of high-flow nasal cannula use for bronchiolitis on the general pediatric floor. J Hosp Med. 2023;18(1):55-58. doi:10.1002/jhm.12994